|hmmm alien thinking?|
'...Full article at the UK's Guardian
That's when Paul told me he'd used the drug, and changed my life.
Talbot's article, like many published since the mid-1990s, turned, in part, on the fuzzy ethics of the use of neuroenhancers. These controversial drugs, strictly licensed for the treatment of narcolepsy, sleep apnoea and ADHD, have become immensely popular among users without prescription because they promote a keen sense of wakefulness and sharper cognitive focus.
It's not known how many people are using neuroenhancers: the drug remains strictly off-licence in the UK and the US. But on 9 November 2011, the BBC's Newsnight tried to get closer to an answer by running an anonymous online questionnaire. There were 761 replies, from New Scientist readers and Newsnight viewers: 38% said they'd taken cognitive-enhancing drugs, 40% said they'd bought the drugs online, and 92% said they'd use them again.
These numbers are crude and anecdotal, and that's because, as Newsnight discovered, it's nigh on impossible to find hard data.
In the first weeks of using modafinil, I felt a bout of happiness, a steadily upward-moving mood; a strange and sustained euphoric effect. I doubt this heightened state was caused by the drug's pharmacological workings. It's more likely to have been brought on by pure relief, perhaps even the power of placebo. After more than two years of being made sluggish and clumsy by MS, my mind muddied and muted, I was wide awake. In the stuffy, darkened house of my head, all the windows and doors seemed to have been flung open and the air was crisp and cool.
I'm not cured of MS, of course – my right hand (and leg) still flags, still stiffens, still weakens – but the effects of modafinil have a way of sacking off the urge to quit. The mysterious workings of the drug seem, somehow, to trump or override physical weakness, and the effects allow me – compel me – to push through the pangs and the pains, and the pesky failings of my right hand.
In this hard-to-describe way, modafinil has revealed something more complicated.
In the US, modafinil has been trialled for MS patients (albeit on a small scale) and the results have been positive. Yet the drug remains off-licence, and in the UK there's still no sign of any major randomised controlled clinical trials.'
She mentions people stopping using them because of the 'too good to be true' factor that begs caution in a Brave New World kinda way to my mind but the below the line comments also reveal the frequency and degree to which the general population tend to conflate cognitive and fatigue impacts with psychological variances.
Curiousier and curiouser
Anyone dabbled? And/or heard of 'neuroenhancers'?